Hugel said Monday that it has registered a patent regarding a method to prepare a liquid formulation comprising a botulinum toxin and a stabilizing agent and buffer.

Hugel's patent is a manufacturing technology to prevent protein-based botulinum toxin from being denatured during development and distribution.

Compared to conventional botulinum toxin that prevented protein denaturation by making the treatment into lyophilized powder form, the technique applies a stabilizing agent and buffer, to liquidity the medication. The liquidation improves stability in the most suitable conditions for the human body such as convenient storage and distribution, body temperature and potential hydrogen (pH).

“Especially, this liquid type technology is meaningful because it proved toxin stabilization effect by using non-animal preparations such as arginine,” the company said.

“To ensure differentiation from existing products, we are working on developing various products such as liquid-free liquid type and attachment types,” Hugel CEO Sohn Ji-hoon said. “As botulinum toxin is not only limited to the cosmetics field, but also in the various other treatments, we expect that this liquid technology patent will contribute to the expansion of global market sales."